Clinical Trial

Evaluation of Spasticity, Neuropathic Pain, and Gait Analysis in Stroke Patients Receiving Tolperison Therapy After Botulinum Toxin Injection

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2026 (before its estimated May 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
Tolperison is an antispastic agent used in the treatment of spasticity. Studies on tolperison are limited, and the literature on its effectiveness against spasticity and neuropathic pain is also limited.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-16.
Trial Details
NCT Number NCT07482618
Lead Sponsor Ayse Guc
Collaborators: Kayseri City Hospital
Conditions Spastic Hemiplegia
Enrollment 40 participants
Start Date 2025-08-13
Primary Completion 2026-05-25 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-20